Azienda Unita Sanitaria Locale Della Romagna
- Address
- lock Available on a paid plan
Neoplasms and Breast Cancer Research
At Azienda Unita Sanitaria Locale Della Romagna, clinical research in neoplasms focuses on breast cancer, especially ER-positive/HER2-negative early breast cancer. The trials are designed to assess new hormone-based treatment approaches and to better understand how they affect tumor activity in premenopausal patients.
- Testing new hormone therapy combinations for early breast cancer
- Comparing treatment strategies to improve anti-proliferative activity
- Evaluating options for metastatic breast cancer
This research aims to improve treatment effectiveness and support more personalized care for women with hormone-sensitive breast cancer.
Hemic and Lymphatic Diseases Studies
Research in hemic and lymphatic diseases includes studies of early stage Follicular Lymphoma and multiple myeloma. These trials are exploring ways to improve disease control, refine response monitoring, and strengthen treatment outcomes in blood cancers.
- Assessing radiotherapy with or without added treatment for Follicular Lymphoma
- Improving minimal residual disease monitoring in multiple myeloma
- Evaluating new combinations to support better treatment effectiveness
The work combines therapeutic research with advanced disease monitoring to help guide care in patients with hematologic malignancies.
Cardiovascular Diseases and Critical Care
Clinical trials in cardiovascular diseases at this site also address critical illness, with a focus on preventing dangerous complications during emergency procedures. The research is centered on improving safety for critically ill adults and reducing the risk of cardiovascular collapse.
- Testing whether early vasopressor therapy can prevent cardiovascular collapse
- Studying safer approaches for patients undergoing endotracheal intubation
- Evaluating strategies to improve emergency care outcomes in critical care
These studies are intended to support faster, safer intervention in high-risk hospital settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 24 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Ascentage Pharma Group Inc.1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Unita Sanitaria Locale Della Romagna
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi | Fondazione Italiana Linfomi Ets | Phase III | Recruiting | Dec 2023 | — |
IMP list
lock Showing 1 of 24 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acalabrutinib | 1 | Unknown | 2024-08-01 | 2024-08-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.